OR WAIT null SECS
March 11, 2015.
The overall output of the Japanese drug industry measured by expected peak sales potential of newly National Health Insurance (NHI)-reimbursed drugs surged to $34 billion between 2010-2014, up from $16.9 billion during 2005-2009, according to Evaluate’s new report, Japan Sales, Volume, Pricing 2015. Highlights of the report include
The full version of the report can be downloaded at